Investor Update

Basel, 17 November 2006

FDA approves Herceptin for the adjuvant treatment of HER2-positive node-positive breast cancer

Dear Investor,
Please find attached a Genentech news release announcing that the U.S. Food and Drug Administration (FDA) approved Herceptin (Trastuzumab), as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel, for the adjuvant treatment of HER2-positive node-positive breast cancer.  Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment – surgery with or without radiation therapy – with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.  

Please do not hesitate to contact us if you have any further questions.